The rising interest for precise characterization of the tumour immune contexture has recently
brought forward the high potential of RNA sequencing (RNA-seq) in identifying molecular …

Over the last decades, transcriptome profiling emerged as one of the most powerful
approaches in oncology, providing prognostic and predictive utility for cancer management …

This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed
sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell …

Genomic analysis of paired tumor–normal samples and clinical data can be used to match
patients to cancer therapies or clinical trials. We analyzed 500 patient samples across …

In a large number of cancer types, treatment selection depends on the presence of specific
tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive …

In recent years, the main quest of science has been the pioneering of the groundbreaking
biomedical strategies needed for achieving a personalized medicine. Ribonucleic acids …

Non-small cell lung cancer (NSCLC) is a serious threat to the health of older adults. Despite
the significant progress in immunotherapy, effective treatments for NSCLC remain limited …

Objective Solid tumors often establish a procoagulable state that can lead to venous
thromboembolism (VTE). Although some of the key genes involved in this process are …

Background & Aims The therapeutic effect of immune checkpoint inhibitors (ICIs) is poor in
hepatocellular carcinoma (HCC) and varies greatly among individuals. Schlafen (SLFN) …

The efficacy of immune checkpoint blockade (ICB) varies greatly among metastatic non-
small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA …